| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| Targets |
HDAC6 (IC50 = 24.4 nM); HDAC3 (IC50 = 187 nM); HDAC11 (IC50 = 245 nM)
|
|---|---|
| ln Vitro |
On the other hand, AES-350 exhibits submicromolar activity (IC50=0.58±0.13 μM) in comparison to vorinostat (IC50=0.31±0.061 μM) against MV4-11 cells. AES-350 exhibits greater ligand efficiency and a broad therapeutic index (IC50>30 μM in MRC-9 cells that are not cancerous). In AML-3 (acute myeloid leukemia) cells, AES-350 has also been demonstrated to be effective (IC50=0.73 ± 0.12 μM)[1].
AES-350 (0.25–4 μM; 18 hours) causes a dose-dependent apoptosis in MV4-11 cells. At a concentration of 0.25 μM–4 μM, the late apoptosis ratios are 8.74%, 11.7%, 16.08%, 30.97%, and 38.48%, respectively[1]. HeLa cervical cancer cell lysates are used for an ELISA; these cells exhibit high levels of HDAC6 expression and are AES-350 sensitive. AES-350 (0.1-10 μM) causes a dose-dependent increase in acetylated α-tubulin (Ac-α-tubulin), a substrate of HDAC. ELISA assays similarly showed a dose-dependent increase in HDAC6 inhibition (IC50=0.58±0.13 μM)[1]. |
| ln Vivo |
AES-350 (oral gavage; 20 mg/kg; single dose) shows comparatively good pharmacokinetic (PK) characteristics in CD-1 mice. The single dose oral bioavailability (F%) of 51 is 19.8%. In comparison, the reported F% for SAHA in mice is significantly lower (8%)[1].
|
| Cell Assay |
Cell Line: MV4-11 cells
Concentration: 0.25 μM; 0.5 μM; 1.00 μM; 2.00 μM; 4.00 μM Incubation Time: 18 hours Result: Revealed a clear dosedependent increase in the percentage of cells entering late-stage apoptosis, similar to SAHA. |
| References |
| Molecular Formula |
C18H20N2O3
|
|---|---|
| Molecular Weight |
312.363
|
| Exact Mass |
312.147
|
| Elemental Analysis |
C, 69.21; H, 6.45; N, 8.97; O, 15.37
|
| CAS # |
847249-57-4
|
| Related CAS # |
847249-57-4
|
| PubChem CID |
11688197
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
4.13
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
23
|
| Complexity |
415
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C1=CC=C(C(NC2=CC=C(C(NO)=O)C=C2)=O)C=C1)(C)C
|
| InChi Key |
FMOQHLZNJFXULZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H20N2O3/c1-18(2,3)14-8-4-12(5-9-14)16(21)19-15-10-6-13(7-11-15)17(22)20-23/h4-11,23H,1-3H3,(H,19,21)(H,20,22)
|
| Chemical Name |
4-tert-butyl-N-[4-(hydroxycarbamoyl)phenyl]benzamide
|
| Synonyms |
AES 350; AES-350; AES350
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~320.1 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.00 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.00 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.00 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2014 mL | 16.0072 mL | 32.0143 mL | |
| 5 mM | 0.6403 mL | 3.2014 mL | 6.4029 mL | |
| 10 mM | 0.3201 mL | 1.6007 mL | 3.2014 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
